SNP information rs121913237

Research and publications:

  2278970   RAS gene mutations in childhood acute myeloid leukemia: a Pediatric Oncology Group study.

  2674680   N-ras mutations in human cutaneous melanoma from sun-exposed body sites.

  3122217   RAS gene mutations in acute and chronic myelocytic leukemias, chronic myeloproliferative disorders, and myelodysplastic syndromes.

  8120410   Ras mutations in human melanoma: a marker of malignant progression.

  12460918   BRAF and RAS mutations in human lung cancer and melanoma.

  14982869   Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia.

  15046639   Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis.

  15831708   Repressible transgenic model of NRAS oncogene-driven mast cell disease in the mouse.

  15951308   RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years.

  16273091   BRAF mutation predicts sensitivity to MEK inhibition.

  16291983   Distinct sets of genetic alterations in melanoma.

  16434492   Implications of NRAS mutations in AML: a study of 2502 patients.

  17332249   Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations.

  17699718   AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in p

  18390968   Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

  18948947   Somatic mutations affect key pathways in lung adenocarcinoma.

  18952898   RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia.

  19075190   High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.

  19657110   Recurring mutations found by sequencing an acute myeloid leukemia genome.

  20130576   RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.

  20179705   RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.

  20619739   Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

  20736745   NRAS mutations are rare in colorectal cancer.

  21305640   Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer.

  21729679   Development of molecular biomarkers in individualized treatment of colorectal cancer.

  21829508   PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers.

  22144181   Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras.

  22407852   RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group.

  22499344   Keratinocytic epidermal nevi are associated with mosaic RAS mutations.

  23414587   MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

  23515407   Characteristics of lung cancers harboring NRAS mutations.

  24033266   A systematic approach to assessing the clinical significance of genetic variants.

  24284627   Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness.

  25157968   Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

  26619011   Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.